Core Viewpoint - The approval of Ryaltris® (GSP 301 NS) by the National Medical Products Administration marks a significant milestone for the company and the introduction of a new treatment option for allergic rhinitis in China, leading the market towards a combination therapy era [1][2]. Group 1: Product Approval and Market Impact - Ryaltris® is a novel combination nasal spray for the treatment of moderate to severe allergic rhinitis in adults and children aged 6 and above, providing a more convenient and effective treatment option [2]. - The market for allergic rhinitis medications in China is projected to grow from 43.275 billion yuan in 2024 to 50.090 billion yuan in 2028, with a compound annual growth rate of approximately 3.72% [1]. - Prior to Ryaltris®, there were no approved combination nasal sprays in China, and existing single-agent nasal sprays were primarily foreign products [1]. Group 2: Company Strategy and Future Development - The successful approval of Ryaltris® is a key milestone for the company's respiratory and critical care segment, showcasing its innovative capabilities in the field of respiratory diseases [2]. - The company is committed to continuing its focus on the research and development of innovative products and advanced technologies, aiming to build a comprehensive product pipeline for chronic airway diseases and critical care [2].

Core Insights - The approval of Ryaltris® (GSP 301 NS) by the National Medical Products Administration marks a significant milestone for the company in the respiratory and critical care sector, showcasing its innovative capabilities in treating allergic rhinitis [1][3] - The entry of Ryaltris® into the market signifies the beginning of a "combination therapy era" in China for allergic rhinitis, providing new treatment options for patients [2] Company Developments - Ryaltris® is a novel combination nasal spray that combines an antihistamine and a corticosteroid, aimed at treating moderate to severe seasonal allergic rhinitis in adults and children aged 6 and above, as well as perennial allergic rhinitis in adults and children aged 12 and above [3] - The product has already been approved in multiple countries, including the United States, Australia, Russia, South Korea, the United Kingdom, and the European Union, indicating its global acceptance and potential market reach [3] - The successful approval of Ryaltris® is a key achievement for the company's respiratory and critical care segment, which is seen as a core strength, with ongoing efforts to address unmet clinical needs through innovative product development [3] Market Context - Allergic rhinitis is a chronic condition that is difficult to cure and has a high recurrence rate, leading to a substantial market opportunity estimated to grow from 43.275 billion yuan in 2024 to 50.090 billion yuan by 2028, with a compound annual growth rate of approximately 3.72% [2] - Currently, the market primarily consists of single-agent formulations, with nasal antihistamines and corticosteroids being the first-line treatments, highlighting the need for combination therapies like Ryaltris® to improve patient outcomes [2]